ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Pediatric Neurology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1569505
Patient demographics, clinical characteristics and genetic mutations of DMD and BMD patients in Qatar
Provisionally accepted
- Sidra Medicine, Doha, Qatar
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are rare X-linked neuromuscular disorders that typically begin in childhood and progress to functional decline, loss of ambulation, and early death due to cardiac or respiratory failure. Objective: To describe the landscape of DMD and BMD in Qatar, including demographics, genetics, disease progression, risk factors, co-morbidities, and outcomes in patients aged 3–30 years, and compare findings with international data. Methods: We retrospectively reviewed records of all genetically confirmed or biopsy-supported cases of DMD and BMD between 2018 and 2024 at Sidra Medicine, the sole pediatric tertiary center in Qatar. Results: Of the 37 symptomatic patients (36 DMD, 1 BMD), 36 were male and one was a symptomatic female. The mean age was 18 years (range 3–30). At diagnosis, median age was 3.0 years. Twenty-two (59%) had orthopedic complications (scoliosis, contractures), 9 (24%) could still run, and 12 (32%) could climb stairs. Corticosteroids were prescribed in 14 patients (38%), most commonly deflazacort and prednisone. Cardiac medications were started in 7 patients (19%) around age 10. CK was elevated in 36/37 (range: 2300–45,000 U/L). Epilepsy was documented in 3 patients; 3 had autism and 1 had ADHD. Genetic mutations included deletions (69%), duplications (11%), and point mutations (19%). Seven patients had mutations affecting Dp140/Dp71 isoforms and cognitive impairment. Conclusions: Our cohort reveals earlier diagnosis but lower life expectancy compared to international standards, likely due to lower corticosteroid and cardioprotective use. The findings support the need for strengthened multidisciplinary and early genetic-based interventions in Qatar Keywords: Duchenne muscular dystrophy, Becker muscular dystrophy, dystrophinopathy, mutation analysis, Qatar, cognitive impairment, gene therapy
Keywords: Duchenne muscular dystrophy, Becker muscular dystrophy, dystrophinopathy, mutation analysis, Qatar, cognitive impairment, Gene Therapy
Received: 31 Jan 2025; Accepted: 14 Jul 2025.
Copyright: © 2025 Sawahreh, Al-Maadid, Ibrahim, Omran and Osman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mahmoud Fawzi Osman, Sidra Medicine, Doha, Qatar
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.